Thymosin-α1 and famciclovir combination therapy activates T cell response in patients with chronic HBV infection in immune tolerant phase.

被引：0
|
作者：
Lau, GK
Nanji, A
Hou, JL
Fong, DY
Yuen, ST
Lai, ST
Leung, YK
Leung, SK
Shiu-Kum, L
机构：
[1] Queen Mary Hosp, Hong Kong, Peoples R China
[2] Nanfang Hosp, Guangzhou, Peoples R China
[3] Clin Trial Ctr, Hong Kong, Peoples R China
[4] Princess Margaret Hosp, Hong Kong, Peoples R China
来源：
HEPATOLOGY | 2001年 / 34卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
610
引用
收藏
页码：324A / 324A
页数：1
相关论文
共 50 条
  • [21] THYMOSIN ALPHA-1 AND CIRCULATING T-CELL SUBSETS IN PATIENTS WITH CHRONIC HEPATITIS-C VIRUS-INFECTION
    SHERMAN, KE
    LIEBERMAN, MM
    FAGARASON, M
    GOLDSTEIN, AL
    HEPATOLOGY, 1993, 18 (04) : A85 - A85
  • [22] Cell-mediated immune responses and loss of hepatitis B e-antigen (HBeAg) during successful lamivudine and famciclovir combination therapy for chronic replicating hepatitis B virus infection
    Hultgren, C
    Weiland, O
    Milich, DR
    Sällberg, M
    CLINICAL INFECTIOUS DISEASES, 1999, 29 (06) : 1575 - 1577
  • [23] Blood transcriptome and clonal T-cell correlates of response and non-response to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia
    Zhang, Haiyu
    Zhang, Bing M.
    Guo, Xiangqian
    Xu, Liwen
    You, Xiaoqing
    West, Robert B.
    Bussel, James B.
    Zehnder, James L.
    HAEMATOLOGICA, 2020, 105 (03)
  • [24] Effect of combined lamivudine and interferon alpha treatment on the T-cell response to HBV core peptides in patients with chronic hepatitis B virus infection
    Cavers, M
    Aw, M
    Sharma, U
    D'Antiga, L
    William, R
    Moorat, A
    Greensmith, M
    Atkins, M
    Mieli-Vergani, G
    Vergani, D
    JOURNAL OF HEPATOLOGY, 2002, 36 : 128 - 129
  • [25] Initiation of antiretroviral therapy during chronic SIV infection leads to rapid reduction in viral loads and the level of T-cell immune response
    Boyer, Jean D.
    Kumar, Sanjeev
    Robinson, Tara
    Parkinson, Rose
    Wu, Ling
    Lewis, Mark
    Watkins, David I.
    Weiner, David B.
    JOURNAL OF MEDICAL PRIMATOLOGY, 2006, 35 (4-5) : 202 - 209
  • [26] INTERFERON ANTIBODIES DIMINISH RESPONSE TO PEGINTERFERON-BASED THERAPY IN THE IMMUNE TOLERANT PHASE OF CHRONIC HEPATITIS B INFECTION: RESULTS FROM THE HEPATITIS B RESEARCH NETWORK (HBRN)
    Feld, Jordan J.
    Zahoor, Atif
    Feld, Joshua B.
    Lin, Hsing-Hua
    Mosa, Alexander
    Perrillo, Robert P.
    Chung, Raymond T.
    Schwarz, Kathleen B.
    Janssen, Harry L.
    Gehring, Adam J.
    HEPATOLOGY, 2022, 76 : S331 - S332
  • [27] Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment
    Rustgi, V
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 : S76 - S78
  • [28] Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment
    Rustgi, V
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (12) : S76 - S78
  • [29] Changes in circulating TCF1- and GARP-associated regulatory T cell subsets reflect the clinical status of patients with chronic HBV infection
    Ayibaota Bahabayi
    Xingyue Zeng
    Bulidierxin Tuerhanbayi
    Yangyang Zhang
    Ainizati Hasimu
    Siyu Guo
    Tianci Liu
    Mohan Zheng
    Xiayidan Alimu
    Chen Liu
    Medical Microbiology and Immunology, 2022, 211 : 237 - 247
  • [30] Changes in circulating TCF1-and GARP-associated regulatory T cell subsets reflect the clinical status of patients with chronic HBV infection
    Bahabayi, Ayibaota
    Zeng, Xingyue
    Tuerhanbayi, Bulidierxin
    Zhang, Yangyang
    Hasimu, Ainizati
    Guo, Siyu
    Liu, Tianci
    Zheng, Mohan
    Alimu, Xiayidan
    Liu, Chen
    MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2022, 211 (5-6) : 237 - 247
12345